1-cyclopropyl-1-methoxyethane | 18022-50-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-cyclopropyl-1-methoxyethane
• 英文别名: (1-methoxyethyl)cyclopropane；<1-Methoxy-ethyl>-cyclopropan, 2-Oxa-3-cyclopropyl-butan；1-Methoxy-1-cyclopropyl-ethan；Methyl-cyclopropyl-carbinol-methylether；(1-Cyclopropyl-aethyl)-methyl-aether；(1-cyclopropyl-ethyl)-methyl ether；1-Methoxyethylcyclopropane
• CAS: 18022-50-9
• 化学式: C₆H₁₂O
• 分子量: 100.161
• InChiKey: WAUSACZHKBGTGF-UHFFFAOYSA-N

物化性质

• 沸点：
  93.8-94.0 °C(Press: 758 Torr)
• 密度：
  0.819 g/cm3

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  7
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-cyclopropyl-1-methoxyethane 在 甲醇 、 对甲苯磺酸 作用下， 生成 (E)-5-methoxypent-2-ene
  参考文献：
  名称：

  Reactions of Methylcyclopropylcarbinyl Derivatives¹

  摘要：

  DOI：

  10.1021/ja01101a015
• 作为产物：
  描述：

  methyl (E)-pent-3-enoate 在 吡啶 、 lithium aluminium tetrahydride 、 calcium carbonate 作用下， 以 甲醇 为溶剂， 反应 312.0h， 生成 1-cyclopropyl-1-methoxyethane
  参考文献：
  名称：

  Hanack,M.; Goerler,K., Chemische Berichte, 1963, vol. 96, p. 2121 - 2126

  摘要：

  DOI：

文献信息

• [EN] PIPERIDINE-DIONE DERIVATIVES<br/>[FR] DÉRIVÉS DE PIPÉRIDINE-DIONE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2015140133A1

  公开（公告）日：2015-09-24

  The invention provides novel compounds having the general formula (I) and tautomers and pharmaceutically acceptable salts thereof, wherein A1, A2, A3, A4, R1, R4, R5, R6, R7 and R8 are as defined herein, compositions including the compounds and methods of using the compounds.

  这项发明提供了具有通式（I）及其互变异构体和药学上可接受的盐的新化合物，其中A1、A2、A3、A4、R1、R4、R5、R6、R7和R8如本文所定义，包括这些化合物的组合物和使用这些化合物的方法。
• Light-Promoted Transfer of an Iridium Hydride in Alkyl Ether Cleavage
  作者：Caleb D. Fast、Nathan D. Schley

  DOI：10.1021/acs.organomet.1c00391

  日期：2021.10.11

  A catalytic, light-promoted hydrosilylative cleavage reaction of alkyl ethers is reported. Initial studies are consistent with a mechanism involving heterolytic silane activation followed by delivery of a photohydride equivalent to a silyloxonium ion generated in situ. The catalyst resting state is a mixture of Cp*Ir(ppy)H (ppy = 2-phenylpyridine-κC,N) and a related hydride-bridged dimer. Trends in

  报道了烷基醚的催化、光促进的氢化硅烷化裂解反应。最初的研究与涉及异解硅烷活化的机制一致，然后传递相当于原位生成的甲硅烷基氧鎓离子的光氢化物。催化剂静止状态是 Cp*Ir(ppy)H (ppy = 2-苯基吡啶-κ C , N) 和相关的氢化物桥接二聚体。底物还原选择性的趋势与 C-O 键断裂的非自由基机制一致。在化学计量测试中发现用蓝光照射 Cp*Ir(ppy)H 会增加氢化物向氧鎓离子的传递速率。在羰基氢化硅烷化催化中发现了类似的速率增强，其通过相关机制起作用，也涉及 Cp*Ir(ppy)H 作为静止状态。
• Substituted Azaspiro(4.5)Decane Derivatives
  申请人：Gruenenthal GmbH

  公开号：US20160016903A1

  公开（公告）日：2016-01-21

  The invention relates to substituted spirocyclic cyclohexane derivatives which have an affinity for the μ opioid receptor and the ORL1 receptor, processes for the preparation thereof, medicaments containing these compounds and the use of these compounds for the preparation of medicaments.

  这项发明涉及对取代的螺环烷环己烷衍生物，其具有对μ阿片受体和ORL1受体的亲和力，以及其制备方法、含有这些化合物的药物和利用这些化合物制备药物的用途。
• Pyrrolopyridazinone Compound
  申请人：Hagihara Masahiko

  公开号：US20090036453A1

  公开（公告）日：2009-02-05

  The present invention discloses a pyrrolopyridazinone compound represented by the formula (1): wherein R 1 represents C 1 -C 2 alkyl group or halogeno C 1 -C 2 alkyl group, R 2 repersents C 3 -C 5 cycloalkyl group, (C 3 -C 5 cycloalkyl)C 1 -C 2 alkyl group or C 1 -C 3 alkyl group, R 3 represents hydrogen atom, or methylene group or cis-vinylene group for forming substituted oxygen-containing hetero ring in combination with group —O—R 2 , R 4 represents hydrogen atom, halogen atom, C 1 -C 8 alkyl group, C 2 -C 6 alkenyl group, C 2 -C 6 alkynyl group, hydroxy C 3 -C 6 alkenyl group, hydroxy C 3 -C 6 alkynyl group, C 1 -C 6 alkyl group substituted by substituent(s) selected from Substituent group (a), C 3 -C 6 cycloalkyl group which may be substituted by substituent(s) selected from Substituent group (b), “C 1 -C 3 alkyl group which is substituted by C 3 -C 6 cycloalkyl group which may be substituted by substituent(s) selected from Substituent group (b), and which may be substituted by a hydroxy group”, an aromatic ring group or heteroaromatic ring group each of which may be substituted by a substituent(s) selected from Substituent group (c) or “C 1 -C 2 alkyl group which is substituted by aromatic ring group or heteroaromatic ring group each of which may be substituted by group(s) selected from Substituent group (c), and which may be substituted by a hydroxy group”, Substituent group (a) represents a halogen atom, hydroxy group, cyano group, carboxy group, C 1 -C 5 alkoxy group, halogeno C 1 -C 4 alkoxy group, C 3 -C 6 cycloalkoxy group, (C 3 -C 6 cycloalkyl)C 1 -C 2 alkoxy group, C 1 -C 4 alkoxycarbonyl group, C 2 -C 4 alkanoyl group, C 2 -C 4 alkanoyloxy group or C 1 -C 4 alkyl-substituted amino group, Substituent group (b) represents a hydroxy group or a halogen atom, Substituent group (c) represents a halogen atom, a hydroxy group, a cyano group, a nitro group, a carboxy group, C 1 -C 5 alkoxy group, C 1 -C 4 alkoxycarbonyl group, C 2 -C 4 alkanoyloxy group, C 1 -C 4 alkyl-substituted amino group or a C 1 -C 4 alkyl group which may be substituted by a substituent(s) selected from the group consisting of (a halogen atom, a hydroxy group and a carboxy group), or a pharmaceutically acceptable salt thereof.

  本发明公开了一种由式（1）表示的吡咯吡啶二酮化合物：其中，R1代表C1-C2烷基或卤代C1-C2烷基，R2代表C3-C5环烷基、（C3-C5环烷基）C1-C2烷基或C1-C3烷基，R3代表氢原子，或与基团-O-R2结合形成取代含氧杂环的亚甲基或顺式乙烯基，R4代表氢原子、卤素原子、C1-C8烷基、C2-C6烯基、C2-C6炔基、羟基C3-C6烯基、羟基C3-C6炔基、由从取代基团（a）中选择的取代基团取代的C1-C6烷基，可由从取代基团（b）中选择的取代基团取代的C3-C6环烷基，可由从取代基团（b）中选择的取代基团取代的C1-C3烷基，且可由羟基取代，芳香环基或杂芳香环基，每个都可由从取代基团（c）中选择的取代基团取代或由取代基团（c）选择的基团取代的C1-C2烷基，且可由羟基取代，取代基团（a）表示卤素原子、羟基、氰基、羧基、C1-C5烷氧基、卤代C1-C4烷氧基、C3-C6环烷氧基、（C3-C6环烷基）C1-C2烷氧基、C1-C4烷氧羰基、C2-C4酰基、C2-C4酰氧基或C1-C4烷基取代的氨基基团，取代基团（b）表示羟基或卤素原子，取代基团（c）表示卤素原子、羟基、氰基、硝基、羧基、C1-C5烷氧基、C1-C4烷氧羰基、C2-C4酰氧基、C1-C4烷基取代的氨基基团或可由从由卤素原子、羟基和羧基组成的基团中选择的取代基团取代的C1-C4烷基，或其药学上可接受的盐。
• 2-(phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors
  申请人：Chau Anh

  公开号：US20090075998A1

  公开（公告）日：2009-03-19

  The invention encompasses novel compounds of Formula I or pharmaceutically acceptable salts thereof. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful to treat pain and/or inflammation from a variety of diseases or conditions, such as osteoarthritis, rheumatoid arthritis and acute or chronic pain. Methods of treating diseases or conditions mediated by the mPGES-1 enzyme and pharmaceutical compositions are also encompassed.

  该发明涵盖了式I的新化合物或其药学上可接受的盐。这些化合物是微粒体前列腺素E合酶-1（mPGES-1）酶的抑制剂，因此可用于治疗多种疾病或情况引起的疼痛和/或炎症，如骨关节炎，类风湿性关节炎和急性或慢性疼痛。还包括治疗由mPGES-1酶介导的疾病或情况的方法和制药组合物。